Maximum Daily Dose of Enoxaparin for VTE Treatment
For treatment of venous thromboembolism in adults, enoxaparin is dosed at 1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg subcutaneously once daily, with no absolute maximum daily dose specified in guidelines—dosing is weight-based without an upper cap. 1, 2
Standard Therapeutic Dosing
The established treatment regimens for VTE are:
- 1 mg/kg subcutaneously every 12 hours (twice daily)
- 1.5 mg/kg subcutaneously once daily
Both regimens are considered equivalent for initial and long-term treatment of VTE 1, 2. The choice between once-daily and twice-daily dosing depends on patient-specific factors, though some post-hoc data suggest twice-daily dosing may be more efficacious 2.
Weight-Based Dosing Without Ceiling
There is no specified maximum daily dose in major guidelines. The dosing remains weight-based regardless of patient size. For example:
- A 100 kg patient would receive 100 mg twice daily (200 mg total daily) or 150 mg once daily
- A 150 kg patient would receive 150 mg twice daily (300 mg total daily) or 225 mg once daily
The available prefilled syringes include strengths up to 150 mg 3, supporting higher total daily doses for heavier patients.
Special Population Considerations
Obesity
In obese patients (BMI >30 kg/m²), continue weight-based dosing but monitor anti-Xa levels. Guidelines acknowledge that optimal dosing is unclear in patients >120 kg 2. Research demonstrates that BMI-stratified therapeutic enoxaparin dosing (with doses ranging up to 200 mg twice daily in patients weighing up to 240 kg) is safe and effective, though 25% required dose reduction and 16% required dose increases based on anti-Xa monitoring 4.
Renal Insufficiency
For patients with severe renal impairment (CrCl <30 mL/min), reduce to 1 mg/kg subcutaneously once daily (not twice daily) 5, 6. This is the only FDA-specified dose adjustment and represents a critical safety modification, as enoxaparin accumulation increases bleeding risk 2-3 fold in severe renal insufficiency 5.
Exercise caution with CrCl 30-50 mL/min, as renal clearance is reduced by 31% at this level 5. Consider dose adjustment or anti-Xa monitoring in this intermediate range.
Low Body Weight
For patients <50 kg, use standard weight-based dosing but exercise caution and consider anti-Xa monitoring 5, 6. Limited data exist for this population, but weight-based dosing remains appropriate.
Monitoring Strategy
Anti-Xa level monitoring is not routinely required but should be considered in:
- Obesity (especially BMI >40 kg/m² or weight >120 kg)
- Renal insufficiency (CrCl 30-50 mL/min)
- Extremes of body weight (<50 kg)
- Pregnancy
- Recurrent VTE despite therapy
- Unexplained bleeding
Target therapeutic anti-Xa levels: 0.5-1.0 IU/mL for twice-daily dosing (measured 4 hours post-dose) or 1.0-2.0 IU/mL for once-daily dosing 7.
Critical Pitfalls to Avoid
- Do not arbitrarily cap the dose at 150 mg or 180 mg daily—this leads to underdosing in heavier patients
- Do not use standard dosing in severe renal impairment (CrCl <30 mL/min)—this significantly increases bleeding risk
- Do not assume once-daily dosing is automatically equivalent to twice-daily in all patients—critically ill patients may require twice-daily dosing for adequate anticoagulation 8
- Do not forget dose adjustment after 1 month in cancer patients receiving long-term therapy with dalteparin (though this doesn't apply to enoxaparin, which maintains the same dose) 1